Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2000, p. 9307-9316, Vol. 20, No. 24
Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical School, Boston,
Massachusetts 02115
Received 26 July 2000/Returned for modification 7 September
2000/Accepted 27 September 2000
The Saccharomyces cerevisiae mRNA capping enzyme
consists of two subunits: an RNA 5'-triphosphatase (Cet1) and an mRNA
guanylyltransferase (Ceg1). In yeast, the capping enzyme is recruited
to the RNA polymerase II (Pol II) transcription complex via an
interaction between Ceg1 and the phosphorylated carboxy-terminal domain
of the Pol II largest subunit. Previous in vitro experiments showed
that the Cet1 carboxy-terminal region (amino acids 265 to 549) carries
RNA triphosphatase activity, while the region containing amino acids
205 to 265 of Cet1 has two functions: it mediates dimerization with
Ceg1, but it also allosterically activates Ceg1 guanylyltransferase
activity in the context of Pol II binding. Here we characterize several
Cet1 mutants in vivo. Mutations or deletions of Cet1 that disrupt
interaction with Ceg1 are lethal, showing that this interaction is
essential for proper capping enzyme function in vivo. Remarkably, the
interaction region of Ceg1 becomes completely dispensable when Ceg1 is
substituted by the mouse guanylyltransferase, which does not require
allosteric activation by Cet1. Although no interaction between Cet1 and
mouse guanylyltransferase is detectable, both proteins are present at yeast promoters in vivo. These results strongly suggest that the primary physiological role of the Ceg1-Cet1 interaction is to allosterically activate Ceg1, rather than to recruit Cet1 to the Pol II complex.
Eukaryotic and viral mRNAs are
modified at their 5' end by a cap structure which consists of a
7-methylguanosine moiety attached to the 5' terminus via a 5'-5'
linkage. Cellular mRNA capping enzyme is a bifunctional enzyme: RNA
5'-triphosphatase removes the Capping enzyme from Saccharomyces cerevisiae is a
heterodimer of RNA triphosphatase and guanylyltransferase subunits
(20) encoded by the CET1 and CEG1
genes, respectively. Both genes are essential for cell viability
(34, 39). CET1 and CEG1 homologs from
Schizosaccharomyces pombe and Candida albicans
functionally replace the S. cerevisiae genes (36, 42,
44). The fungal guanylyltransferase subunits have amino acid
similarity to viral and metazoan guanylyltransferases, indicating a
common reaction mechanism (11, 41). In contrast to the two
subunit yeast enzymes, capping enzyme from higher eukaryotes are a
single polypeptide consisting of an amino-terminal RNA triphosphatase
domain and a carboxy-terminal guanylyltransferase domain. Both mouse
(MCE or MCE1) and human (HCE or HCE1) enzymes can replace
CEG1 and CET1 in vivo (16, 17, 24, 43,
47). Interestingly, the higher eukaryotic RNA triphosphatase
domains belong to the PTP (protein tyrosine phosphatase) superfamily
(27, 38, 47) and do not resemble the fungal phosphatases
(39, 44).
Cellular capping enzymes are recruited to the phosphorylated
carboxy-terminal domain (CTD-P) of the RNA polymerase II (Pol II)
largest subunit (2, 27, 47). In vitro studies showed that
Ceg1 directly binds to CTD-P (3, 27), while Cet1 does not
(3). Surprisingly, covalent enzyme-GMP complex formation by
Ceg1 is inhibited by binding to CTD-P, and Cet1 is required to
reactivate Ceg1 (3). In the mammalian system, the
guanylyltransferase domain interacts with CTD-P (17, 47),
whereas the RNA triphosphatase domain does not (17).
The RNA 5'-triphosphatase activity of Cet1 is carried in its C-terminal
region (amino acids 265 to 549) (16, 30, 39). Previously,
our in vitro results showed that residues 205 to 265 of Cet1 are
necessary and sufficient for both the interaction with Ceg1 and the
allosteric activation of Ceg1 on CTD-P (3). Here we further
analyze this interaction in vivo. We find that the region of Cet1 that
interacts with Ceg1 is normally essential but becomes dispensable if
Ceg1 is replaced by the mouse guanylyltransferase. This strongly
suggests that the Ceg1-Cet1 interaction is essential for the positive
allosteric activation of Ceg1 but not for delivering Cet1 to the
transcription complex.
DNA cloning methods.
Supplementary tables describing the
construction of plasmids and oligonucleotides used in this study are
available from the Buratowski Lab website
(http://tfiib.med.harvard.edu/pubs/Takase.html). Standard methods were
used. Yeast plasmids were based on the pRS series (37). PCRs
for the construction of plasmids and site-directed mutagenesis were
carried out with Vent DNA polymerase (New England BioLabs).
Genetic manipulations of S. cerevisiae.
Table
1 lists the S. cerevisiae
strains used in this study. Plasmids were introduced into yeast using a
modified lithium acetate transformation protocol (8). Medium
preparation, plasmid shuffling, and other yeast manipulations were
performed by standard methods (1, 10).
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Essential Interaction between Yeast mRNA
Capping Enzyme Subunits Is Not Required for Triphosphatase Function
In Vivo

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-phosphate from the 5' end of the RNA
substrate to leave a diphosphate end, and GTP::mRNA
guanylyltransferase subsequently transfers GMP from GTP to the
5'-diphosphate RNA end. A separate enzyme, RNA
(guanine-7-)-methyltransferase, adds a methyl group to the N-7 position
of the guanine cap to leave m7GpppN1-
(35).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Yeast strains used in this study
1 (CEN/ARS,
URA3) in which the portion encoding N-terminal region (amino
acids 1 to 265) of CET1 open reading frame was replaced with
TRP1 gene. In sporulating and dissecting tetrads of
Trp+ transformants, viability segregated 2:2, and all
viable spores were Trp
. The diploid carrying the
cet1
::TRP1 locus was transformed with pRS316-CET1 and sporulated to create haploid strains YSB532
and YSB533.
A CET1 CEG1 double disruption strain was created as follows:
a 4.8-kb EcoRI/SalI fragment from pBS-LYS2
containing the LYS2 gene was subcloned into the
EcoRI and XhoI sites of pBSKS(+)(
RI-X)-CEG1 (6). The resulting plasmid
[pBSKS(+)(
RI-X)-ceg1
3::LYS2] releases a 5.5-kb
fragment of ceg1
3::LYS2 with
NotI/PstI digestion. YSB532 was transformed with
pRS313-CET1, and transformants were selected which were
His+ and resistant to 5-fluoro-orotic acid (5-FOA). This
strain (YSB540) was then transformed with pRS316-CEG1 (6)
and the 5.5-kb fragment from
pBSKS(+)(
RI-X)-ceg1
3::LYS2, and transformants were
selected which were Trp+, Ura+, and
Lys+ and 5-FOA sensitive. Then, pRS315-CEG1 (6)
was introduced, and pRS316-CEG1 was shuffled out with 5-FOA. Finally,
pRS316-CEG1-CET1 was used for transformation, and Trp+
Lys+ Ura+ His
Leu
cells were selected to generate YSB719.
Yeast two-hybrid assays were carried out with strain HF7c using the
GAL4-dependent HIS3 reporter gene (5). pAS1
plasmid was used for expression of Gal4 DNA binding domain fusions
(4). Either pGAD-C1 (21) or pY2 (31)
was used for Gal4 activation domain fusions. Leu+
Trp+ transformants were selected and tested for their
viability in the absence of histidine on plates containing 1 mM
3-aminotriazole.
Site-directed mutagenesis. Site-directed mutagenesis was performed using a PCR-mediated method (14) with three mutagenic primers: CET1P238/Y241mut, CET1P245/W247mut, and CET1W251/P253mut.
To introduce the PCR product into yeast, a single-step method based on gap repair was used (13, 28). The mutagenized DNA was transformed into YSB533 together with a 7.6-kb BglII/BglII fragment of pRS315-CET1 which removes much of the coding region but carries overlap with each end of the PCR product to allow recombination. After transformation, the wild-type CET1/URA3 plasmid was shuffled out on medium containing 5-FOA. Plasmid DNA was isolated from 5-FOA resistant cells and sequenced to confirm the mutations.Isolation of cet1 conditional alleles by random mutagenesis. The CET1 gene was randomly mutagenized by a PCR-based misincorporation method (28). Reactions contained 1 U of Taq DNA polymerase, 0.3 µM CET1-A and CET1-B as primers, 0.25 mM MnCl2, and biased deoxynucleoside triphosphate concentrations (0.4 mM dGTP, dCTP, and dTTP and 0.1 mM dATP). The reaction was cycled 30 times for 1 min at 94°C, 1 min at 57°C, and 2 min at 72°C.
The mutagenized DNA was transformed into YSB533 together with a 7.6-kb BglII/BglII fragment of pRS315-CET1 as described above. After shuffling out the wild-type CET1 plasmid, FOA-resistant cells were replica plated at 16, 30, and 37°C to screen for heat sensitivity and cold sensitivity. Plasmid DNA was isolated from heat- and cold-sensitive mutants and retransformed to YSB533 to confirm plasmid linkage. Several tight alleles were selected for further analysis and sequenced.Preparation of antibodies. Anti-Cet1 polyclonal antiserum was raised in a rabbit by immunizing with a bacterially produced carboxy-terminal region of Cet1 (amino acids 265 to 549) fused with polyhistidine tag and 13 extra residues at the amino terminus [His7-Cet1(265-549) (3)]. The protein was purified by chromatography over Ni2+-nitrilotriacetic acid (NTA) agarose (Qiagen) and S-Sepharose FF (Pharmacia).
Anti-Abd1 polyclonal antiserum was raised in a rabbit by immunizing with a bacterially produced polyhistidine-tagged Abd1 protein. His7-Abd1 was purified from the soluble fraction by Ni2+-NTA agarose chromatography (26) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12). For immunoaffinity purification of anti-Cet1 antibody, Cet1(265-549) fused to glutathione S-transferase was expressed in BL21(DE3) cells using pSBET-GEXCT-CET1(265-549), a derivative of pSBET and pETGEXCT (32, 33). Lysates were prepared by sonication in buffer B (Tris-HCl, pH 8.0; 300 mM KCl; 1 mM EDTA; 1 mM dithiothreitol [DTT]; 1 mM phenylmethylsulfonyl fluoride [PMSF]; 0.5% [vol/vol] NP-40). Purification and cleavage of the fusion protein was carried out as described earlier (9), with the following modifications. Soluble extract (100,000 × g supernatant fraction) were incubated in batch with glutathione agarose (Sigma) for 2 h at 4°C on a rotator. The resin was successively washed with about 5 bed volumes of PBST and 1 bed volume of buffer C (50 mM Tris-HCl, pH 8.0; 150 mM KCl; 2.5 mM CaCl2; 1 mM DTT; 1 mM PMSF). Beads were then resuspended in buffer C (50% [vol/vol]), and 5 µg of thrombin (Calbiochem) was added. The cleavage reaction was for 40 h at 4°C on a rotator. The resin was then poured into a column and eluted with 2 bed volumes of buffer C. Cleaved Cet1(265-549) was dialyzed against buffer D (20 mM Tris-HCl, pH 7.5; 20 mM KCl; 1 mM EDTA; 1 mM DTT; 1 mM PMSF). The protein was crosslinked to CNBr-activated Sepharose 4B (Pharmacia), and antibody was immunopurified as described elsewhere (12).Yeast whole-cell extract preparation and protein analysis.
Whole-cell extracts from S. cerevisiae were prepared by
glass bead disruption of cells in lysis buffer (20 mM Tris-HCl, pH 7.9;
1 mM EDTA; 200 mM KCl; 10% [vol/vol] glycerol; 1 mM DTT; 1 mM PMSF).
Equivalent amounts of protein from each sample were then subjected to
either immunoblot analysis with enhanced chemiluminescence detection or
enzyme-GMP formation assay with 3 µM [
-32P]GTP
(30,000 to 60,000 cpm/pmol; NEN) (6).
-32P]GTP), and
the reaction mixture was incubated for 15 min at 30°C. The labeled
guanylyltransferase-GMP complex was resolved by SDS-PAGE and visualized
by using a phosphorimager.
Chromatin immunoprecipitation. Preparation of chromatin from S. cerevisiae, immunoprecipitation, and quantitative analysis of precipitated DNA were carried out as described previously (22, 23).
| |
RESULTS |
|---|
|
|
|---|
Deletion analysis of Cet1 in vivo.
We constructed a truncation
series in Cet1 and tested them for function in vivo by plasmid
shuffling (Fig. 1A). Each mutant was
expressed under the control of the native CET1 promoter on a
centromeric plasmid. CET1(205-549) supported cell viability with no apparent difference in growth from wild-type cells (colonies formed after 2 days). Therefore, the N-terminal 205 amino acids of Cet1
are dispensable in vivo, in agreement with the findings of Ho et al.
(16). In contrast, CET1(265-549) cells were
unable to grow even though this region is sufficient for its enzymatic activity (30). Amino acids 205 to 265 are required for
interaction with Ceg1 in vitro (3), so it appears this
interaction is essential for cell viability.
|
Mutational analysis of the Ceg1 interaction region of Cet1.
Our results and those of others (19, 24) indicated that one
or more residues between amino acids 235 and 265 must be critical for
binding to Ceg1. On the basis of the alignment between Cet1 and its
C. albicans homologue (CaCet1 [44]) (Fig.
2A), we mutagenized six conserved
residues to generate the following alleles: cet1-441 (P238A,
K240N, and Y241A), cet1-442 (P238A), cet1-446
(P245A, W247A), cet1-448 (W247A), cet1-450 (W251A
and P253L), and cet1-451 (W251A). We expressed these mutants
in the
cet1 strain on a centromeric plasmid and tested
them for complementation by plasmid shuffling. Cells containing
cet1-441, cet1-442, cet1-450, and
cet1-451 were viable without any abnormal phenotype. In
contrast, cet1-446 was lethal, and cells with
cet1-448 grew normally at 30°C but not at 37°C.
Therefore, it is likely that both Trp-247 and Pro-245 of Cet1 are
important for interaction with Ceg1. Yeast strains containing the
cet1-446 and cet1-448 alleles were tested by
immunoblotting, and it was found that these mutant proteins were stably
expressed at both permissive and nonpermissive temperatures (Fig. 2C).
|
Mutational analysis of the CET1 catalytic region.
Several temperature-sensitive alleles of CET1 were isolated
using random mutagenesis by PCR-based misincorporation. All mutants isolated in this screen were in the catalytic region (amino acids 265 to 549). Some mutants had multiple changes, so single point mutant
alleles were constructed and tested to isolate the changes relevant to
their temperature sensitivities. cet1-401 (D422A) and
cet1-438 (C330W) showed a severe growth defect at 37°C,
while cet1-331.1 (K427E) grew normally at 30 and 37°C but
not at 16°C (Fig. 3A and B).
|
sheets (25). D422 is located in a turn between two antiparallel
sheets (
7 and
8) and is partially solvent accessible. It is likely that this residue contributes to overall folding of the enzyme. C330 is in the
3 sheet and appears to contribute to the Cet1-Cet1 dimer interface
within the crystal. Interestingly, K427 is in the
8 sheet at the
edge of the Cet1 active-site tunnel, suggesting that the cold
sensitivity of cet1-331.1 might be due to defective
interactions with the substrate RNA. Sequence alignment of Cet1 with
CaCet1 and Ctl1-Cth1 (another S. cerevisiae RNA phosphatase
not associated with capping enzyme [29, 30]) shows
that K427 is conserved in Ctl1 and an arginine in CaCet1, that C330 is
only conserved in CaCet1, and that D422 is not conserved in the other
two proteins. Immunoblotting showed that both cet1-401
(D422A) and cet1-438 (C330W) were degraded at the
nonpermissive temperature (Fig. 3C). The cold-sensitive allele
cet1-331.1 produced a protein that was stable at 16°C
(data not shown).
Suppression of cet1 conditional phenotypes by
overexpression of guanylyltransferase.
Overexpression of Cet1
suppresses some ceg1 temperature-sensitive alleles,
presumably by stabilizing the mutant Ceg1 protein (3, 16).
We tested the converse, whether overexpression of Ceg1 could suppress
cet1 conditional phenotypes. Either Ceg1 or the mouse
guanylyltransferase domain [Mce(211-597)] were expressed from
high-copy plasmids in a
ceg1
cet1 strain. A
URA3-marked plasmid carrying wild-type CET1 was
replaced with the indicated CET1 alleles by plasmid
shuffling, and the resulting strains were tested for viability at 30 and 37°C (Fig. 4A and B).
|
Expression of mouse capping enzyme guanylyltransferase bypasses the requirement for the interaction domain of Cet1. The physiological role of Cet1 amino acids 205 to 265 could be to recruit RNA triphosphatase activity (residues 265 to 549 of Cet1) to the Pol II initiation complex via binding to Ceg1 and/or to activate Ceg1 guanylyltransferase bound to the phosphorylated CTD (3). The mammalian RNA triphosphatase domain is structurally and mechanistically unrelated to Cet1 (27, 47). In the mammalian system, the phosphorylated CTD interacts with the guanylyltransferase domain and not the RNA triphosphatase domain (17, 47). In contrast to the fungal guanylyltransferase inhibition (3), the ability of the mouse guanylyltransferase (both the full-length enzyme and the isolated guanylyltransferase domain) to form the enzyme-GMP complex is stimulated by binding to phosphorylated CTD (18). Therefore, mammalian guanylyltransferase expressed in yeast presumably does not need to be allosterically activated by Cet1. On the other hand, Cet1 still must get to the transcription complex to carry out the first step of mRNA capping. Therefore, we expected that the mouse guanylyltransferase domain would allow us to assess the two functions of Cet1(205-265) in vivo.
Mammalian full-length enzymes complement null and conditional mutants of CEG1 and/or CET1 if expressed under a strong constitutive promoter and/or from a high copy plasmid (16, 24, 43, 47).
ceg1
cet1 cells with MCE under the control
of the native CET1 promoter on a centromeric plasmid grew
very slowly (Y. Takase, unpublished observations). Cells with
MCE(211-597) and CET1(265-549) grew poorly if the latter
was supplied by a centromeric plasmid (Takase, unpublished). Therefore,
we coexpressed Cet1(265-549) and Mce(211-597) from high-copy vectors
and tested their ability to replace the wild-type Ceg1 and Cet1 by
plasmid shuffling in
ceg1
cet1 cells (Fig.
5A). As previously observed,
Cet1(265-549) did not support cell growth when guanylyltransferase
activity was supplied by Ceg1. However, in cells expressing the mouse
guanylyltransferase domain, Cet1(265-549) supported growth almost as
well as full-length Cet1. Using enzyme-GMP complex formation (Fig. 5B,
left panel) and immunoblotting (Fig. 5B, right panel), neither
full-length Cet1 or Ceg1 protein was detected (lane 3), confirming that
the wild-type copies of the corresponding genes were shuffled out of
these cells. These results clearly demonstrate that amino acids 205 to
265 of Cet1 are not absolutely required under all conditions.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The Cet1 mRNA triphosphatase plays two crucial roles in capping. Its carboxy-terminal region (amino acids 265 to 549) catalyzes the first step of cap synthesis while a second region (amino acids 205 to 265) binds to Ceg1 and allosterically activates the guanylyltransferase when it is bound to the phosphorylated CTD of Pol II (3). In this report, we study the interaction between the yeast capping enzyme subunits and come to the surprising conclusion that its primary role is not to recruit Cet1 to the promoter. Because the requirement for Cet1 amino acids 205 to 265 is observed with guanylyltransferase from S. cerevisiae but not from mammals, it is likely that the major purpose of the Ceg1-Cet1 interaction is the allosteric activation previously documented in vitro.
Both plasmid shuffling and two-hybrid analysis (Fig. 1) indicate that amino acids 235 to 265 of Cet1 are necessary and sufficient for interaction with Ceg1. We found that at least four residues in this region (P238, W247, W251, and P253) are important for this function (Fig. 2). Recently, an alanine scanning study of amino acids 247 to 251 found that a W247A-Q249A mutant is nonviable and a K250A-W251A mutant causes conditional lethality, but a P245A-I246A mutant did not affect cell viability (19, 24). Overall, our results are in good agreement with those studies. The crystal structure study of Cet1(241-539) shows that this region is exposed on the surface, with the side chains of both W247 and W251 accessible for binding to Ceg1 (25). The interaction studies are also supported by allele specific suppression of cet1 mutants by CEG1 overexpression (Fig. 4). The temperature-sensitive cet1-448 allele is mutated in the subunit interaction domain and makes a stable protein. Increased levels of Ceg1 suppress the conditional phenotype of cet1-448 by driving the Ceg1-Cet1 interaction. In contrast, catalytic domain mutants cet1-401 and cet1-438 are unstable and are not significantly suppressed by Ceg1 overexpression.
Since the mouse guanylyltransferase domain supports viability in a
ceg1 strain (17; T. Takagi,
unpublished observations), it might be predicted that Mce(211-597)
would bind to full-length Cet1 and guide it to the phosphorylated CTD.
Peptide-affinity chromatography showed that Mce(211-597) can bind
weakly to residues 232 to 265 of Cet1 in vitro (19).
However, glycerol gradient sedimentation (16), yeast
two-hybrid assay (Takagi, unpublished), and immunoprecipitation of
yeast extracts (Fig. 5C) argue against any physiological interaction
between mouse guanylyltransferase and the yeast triphosphatase.
Interestingly, Mce(211-597) suppresses the lethality of the
interaction domain mutant cet1-446, whereas Ceg1
overexpression does not (Fig. 4). This suggests that the manner of
suppression of cet1-448 by Mce(211-597) is different from
that of Ceg1. Also, cet1-401 and cet1-438 cannot
support viability if Ceg1 is replaced with mouse guanylyltransferase
(Fig. 4C). We speculate that binding to Ceg1 helps stabilize these
triphosphatase mutants and that Mce(211-597) cannot carry out this
function because it does not bind to Cet1.
The final and strongest piece of evidence that mouse
guanylyltransferase does not function by binding to the Ceg1
interaction domain of Cet1 is that this region (amino acids 205 to 265 of Cet1) becomes completely dispensable in the presence of the
MCE(211-597). Guanylyltransferase from some species can modify a
triphosphate end of RNA in vitro to form an unusual tetraphosphate cap
structure, GppppN1- (40, 46). However,
ceg1
cet1 cells with Mce(211-597) still require the
RNA triphosphatase. Therefore, the mouse guanylyltransferase bypasses
the requirement for the interaction domain of Cet1 but not the
requirement for the catalytic domain. We tested whether the two
functions of Cet1 could be supplied on different proteins. Coexpression
of Cet1(1-265) and Cet1(265-549) in the presence of Ceg1 did not
support viability (Takase, unpublished), but this may be due to
instability or inability of Cet1(1-265) protein to localize in the nucleus.
How does Cet1(265-549) get to the nascent mRNA when not chaperoned by guanylyltransferase? In vitro experiments suggest that Cet1 itself does not bind to the phosphorylated CTD (3). We did not detect any interaction of Cet1 with Mce(211-597) by immunoprecipitation (Fig. 5C) or yeast two-hybrid assay. Nevertheless, in vivo cross-linking of Cet1 in the presence of the mouse guanylyltransferase shows that it is still present at the promoter. Therefore, there must be some guanylyltransferase-independent pathway for the recruitment of Cet1 to the transcription complex, perhaps via interactions with the RNA, with another part of the polymerase, or with some other promoter-localized factor.
In summary, we find that the Ceg1-interacting domain of the mRNA triphosphatase Cet1 is essential for viability but not for delivering Cet1 to the promoter. The requirement for this domain is alleviated when the yeast guanylyltransferase Ceg1 is substituted with the mammalian guanylyltransferase. Since Ceg1, but not the mouse guanylyltransferase, is allosterically activated by Cet1, we propose that this is the essential function of the interaction between yeast capping enzyme subunits. So far, all yeast capping enzymes studied consist of two subunits. If the allosteric interaction turns out to be a general property of fungal capping enzymes, one can envision targeting this feature to design antifungal drugs that would not affect the mammalian host enzyme.
| |
ACKNOWLEDGMENTS |
|---|
We thank A. Sharrocks (University of Newcastle) for pETGEXCT, A. Shatkin and R. Pilluta (Center for Advanced Biotechnology and Medicine, Piscataway, N.J.) for pG-MCE, and F. Winston (Harvard Medical School) for pAD5 and FB235. We are grateful to members of the Buratowski lab, particularly L. Fresco-Cohen for Abd1 antiserum, C. Rodriguez for contributions in the initial phase of this project, V. Polodny for help sequencing, and R. Buratowski for help in making tables.
This work was supported by NIH grant GM56663 to S.B. T.T. was a Senior Postdoctoral Fellow of the American Cancer Society, Massachusetts Division, Inc. S.B. is a Scholar of the Leukemia and Lymphoma Society.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115. Phone: (617) 432-0696. Fax: (617) 738-0516. E-mail: steveb{at}hms.harvard.edu.
Present address: Eisai Tsukuba Research Laboratories, Ibaraki
300-26, Japan.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1991. Current protocols in molecular biology. John Wiley & Sons, New York, N.Y. |
| 2. |
Cho, E.-J.,
T. Takagi,
C. R. Moore, and S. Buratowski.
1997.
mRNA capping enzyme is recruited to the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal domain.
Genes Dev.
11:3319-3326 |
| 3. |
Cho, E.-J.,
C. R. Rodriguez,
T. Takagi, and S. Buratowski.
1998.
Allosteric interaction between capping enzyme subunits and the RNA polymerase II carboxy-terminal domain.
Genes Dev.
12:3482-3487 |
| 4. |
Durfee, T.,
K. Becherer,
P.-L. Chen,
S.-H. Yeh,
Y. Yang,
A. E. Kilburn,
W.-H. Lee, and S. J. Elledge.
1993.
The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.
Genes Dev.
7:555-569 |
| 5. |
Feilotter, H. E.,
G. J. Hannon,
C. J. Ruddell, and D. Beach.
1994.
Construction of an improved host strain for two hybrid screening.
Nucleic Acids Res.
22:1502-1503 |
| 6. |
Fresco, L. D., and S. Buratowski.
1994.
Active site of the mRNA-capping enzyme guanylyltransferase from Saccharomyces cerevisiae: similarity to the nucleotidyl attachment motif of DNA and RNA ligases.
Proc. Natl. Acad. Sci. USA
91:6624-6628 |
| 7. | Fresco, L. D., and S. Buratowski. 1996. Conditional mutants of the yeast mRNA capping enzyme show that the cap structure enhances, but is not required for, mRNA splicing. RNA 2:584-595[Abstract]. |
| 8. |
Gietz, D.,
A. St. Jean,
R. A. Woods, and R. Schiestl.
1992.
Improved method for high efficiency transformation of intact yeast cells.
Nucleic Acids Res.
20:1425 |
| 9. | Guan, K., and J. E. Dixon. 1991. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192:262-267[CrossRef][Medline]. |
| 10. | Guthrie, C., and G. R. Fink (ed.). 1991. Methods in enzymology, vol. 194. Guide to yeast genetics and molecular biology. Academic Press, Inc., San Diego, Calif. |
| 11. | Hakansson, K., A. J. Doherty, S. Shuman, and D. B. Wigley. 1997. X-ray crystallography reveals a large conformational change during guanylyl transfer by mRNA capping enzyme. Cell 89:545-553[CrossRef][Medline]. |
| 12. | Harlow, E., and D. Lane (ed.). 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 13. | Hirschhorn, J. N., D. B. Bortvin, S. L. Ricupero-Hovasse, and F. Winston. 1995. A new class of histone H2A mutations in Saccharomyces cerevisiae causes specific transcription defects in vivo. Mol. Cell. Biol. 15:1999-2009[Abstract]. |
| 14. | Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59[CrossRef][Medline]. |
| 15. |
Ho, C. K.,
Y. Pei, and S. Shuman.
1998.
Yeast and viral RNA 5' triphosphatases comprise a new nucleoside triphosphatase family.
J. Biol. Chem.
273:34151-34156 |
| 16. |
Ho, C. K.,
B. Schwer, and S. Shuman.
1998.
Genetic, physical, and functional interactions between the triphosphatase and guanylyltransferase components of the yeast mRNA capping apparatus.
Mol. Cell. Biol.
18:5189-5198 |
| 17. |
Ho, C. K.,
V. Sriskanda,
S. McCracken,
D. Bentley,
B. Schwer, and S. Shuman.
1998.
The guanylyltransferase domain of mammalian mRNA capping enzyme binds to the phosphorylated carboxyl-terminal domain of RNA polymerase II.
J. Biol. Chem.
273:9577-9585 |
| 18. | Ho, C. K., and S. Shuman. 1999. Distinct roles for CTD Ser-2 and Ser-5 phosphorylation in the recruitment and allosteric activation of mammalian mRNA capping enzyme. Mol. Cell 3:405-411[CrossRef][Medline]. |
| 19. |
Ho, C. K.,
K. Lehman, and S. Shuman.
1999.
An essential surface motif (WAQKW) of yeast RNA triphosphatase mediates formation of the mRNA capping enzyme complex with RNA guanylyltransferase.
Nucleic Acids Res.
27:4671-4678 |
| 20. |
Itoh, N.,
H. Yamada,
Y. Kaziro, and K. Mizumoto.
1987.
Messenger RNA guanylyltransferase from Saccharomyces cerevisiae: large scale purification, subunit functions, and subcellular localization.
J. Biol. Chem.
262:1989-1995 |
| 21. | James, P., J. Halladay, and E. A. Craig. 1996. Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. Genetics 144:1425-1436[Abstract]. |
| 22. |
Komarnitsky, P. B.,
E.-J. Cho, and S. Buratowski.
2000.
Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription.
Genes Dev.
14:2452-2460 |
| 23. | Kuras, L., and K. Struhl. 1999. Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme. Nature 399:609-613[CrossRef][Medline]. |
| 24. |
Lehman, K.,
B. Schwer,
C. K. Ho,
I. Rouzankina, and S. Shuman.
1999.
A conserved domain of yeast RNA triphosphatase flanking the catalytic core regulates self-association and interaction with the guanylyltransferase component of the mRNA capping apparatus.
J. Biol. Chem.
274:22668-22678 |
| 25. | Lima, C. D., L. K. Wang, and S. Shuman. 1999. Structure and mechanism of yeast RNA triphosphatase: an essential component of the mRNA capping apparatus. Cell 99:533-543[CrossRef][Medline]. |
| 26. | Mao, X., B. Schwer, and S. Shuman. 1995. Yeast mRNA cap methyltransferase is a 50-kilodalton protein encoded by an essential gene. Mol. Cell. Biol. 15:4167-4174[Abstract]. |
| 27. |
McCracken, S.,
N. Fong,
E. Rosonina,
K. Yankulov,
G. Brothers,
D. Siderovski,
A. Hessel,
S., S. Foster,
Amgen EST Program,
S. Shuman, and D. L. Bentley.
1997.
5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II.
Genes Dev.
11:3306-3318 |
| 28. | Mulhard, D., R. Hunter, and R. Parker. 1992. A rapid method for localized mutagenesis of yeast genes. Yeast 8:79-82[CrossRef][Medline]. |
| 29. |
Pei, Y.,
C. K. Ho,
B. Schwer, and S. Shuman.
1999.
Mutational analyses of yeast RNA triphosphatases highlight a common mechanism of metal-dependent NTP hydrolysis and a means of targeting enzymes to pre-mRNAs in vivo by fusion to the guanylyltransferase component of the capping apparatus.
J. Biol. Chem.
274:28865-28874 |
| 30. |
Rodriguez, C. R.,
T. Takagi,
E.-J. Cho, and S. Buratowski.
1999.
A Saccharomyces cerevisiae RNA 5'-triphosphatase related to mRNA capping enzyme.
Nucleic Acids Res.
27:2181-2188 |
| 31. | Sadowski, I., B. Bell, P. Broad, and M. Hollis. 1992. GAL4 fusion vectors for expression in yeast or mammalian cells. Gene 118:137-141[CrossRef][Medline]. |
| 32. | Schenk, P. M., S. Baumann, R. Mattes, and H.-H. Steinbiss. 1995. Improved high-level expression system for eukaryotic genes in Escherichia coli using T7 RNA polymerase and rare argtRNAs. BioTechniques 19:196-200[Medline]. |
| 33. | Sharrocks, A. D. 1994. A T7 expression vector for producing N- and C-terminal fusion proteins with glutathione S-transferase. Gene 138:105-108[CrossRef][Medline]. |
| 34. |
Shibagaki, Y.,
N. Itoh,
H. Yamada,
S. Nagata, and K. Mizumoto.
1992.
mRNA capping enzyme: isolation and characterization of the gene encoding mRNA guanylyltransferase subunit from Saccharomyces cerevisiae.
J. Biol. Chem.
267:9521-9528 |
| 35. | Shuman, S. 1995. Capping enzyme in eukaryotic mRNA synthesis. Prog. Nucleic Acids Res. Mol. Biol. 50:101-129[Medline]. |
| 36. |
Shuman, S.,
Y. Liu, and B. Schwer.
1994.
Covalent catalysis in nucleotidyl transfer reactions: essential motifs in Saccharomyces cerevisiae RNA capping enzyme are conserved in Schizosaccharomyces pombe and viral capping enzymes and among polynucleotide ligases.
Proc. Natl. Acad. Sci. USA
91:12046-12050 |
| 37. |
Sikorski, R. S., and P. Hieter.
1989.
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.
Genetics
122:19-27 |
| 38. | Takagi, T., C. R. Moore, F. Diehn, and S. Buratowski. 1997. An RNA 5'-triphosphatase related to the protein tyrosine phosphatases. Cell 89:867-873[CrossRef][Medline]. |
| 39. |
Tsukamoto, T.,
Y. Shibagaki,
S. Imajoh-Ohmi,
T. Murakoshi,
M. Suzuki,
A. Nakamura,
H. Gotoh, and K. Mizumoto.
1997.
Isolation and characterization of the yeast mRNA capping enzyme subunit gene encoding RNA 5'-triphosphatase, which is essential for cell viability.
Biochem. Biophys. Res. Commun.
239:116-122[CrossRef][Medline].
|
| 40. |
Wang, D., and A. J. Shatkin.
1984.
Synthesis of Gp4N and Gp3N compounds by guanylyltransferase purified from yeast.
Nucleic Acids Res.
12:2303-2315 |
| 41. |
Wang, S. P.,
L. Deng,
C. K. Ho, and S. Shuman.
1997.
Phylogeny of mRNA capping enzyme.
Proc. Natl. Acad. Sci. USA
94:9573-9578 |
| 42. |
Yamada-Okabe, T.,
O. Shimmi,
R. Doi,
K. Mizumoto,
M. Arisawa, and H. Yamada-Okabe.
1996.
Isolation of the mRNA-capping enzyme and ferric-reductase-related genes from Candida albicans.
Microbiology
142:2515-2523 |
| 43. |
Yamada-Okabe, T.,
R. Doi,
O. Shimmi,
M. Arisawa, and H. Yamada-Okabe.
1998.
Isolation and characterization of a human cDNA for mRNA 5'-capping enzyme.
Nucleic Acids Res.
26:1700-1706 |
| 44. | Yamada-Okabe, T., T. Mio, M. Matsui, Y. Kashima, M. Arisawa, and H. Yamada-Okabe. 1998. Isolation and characterization of the Candida albicans gene for mRNA 5'-triphosphatase: association of mRNA 5'-triphosphatase and mRNA 5'-guanylyltransferase activities is essential for the function of mRNA 5'-capping enzyme in vivo. FEBS Lett. 435:49-54[CrossRef][Medline]. |
| 45. |
Yamada-Okabe, T.,
T. Mio,
Y. Kashima,
M. Matsui,
M. Arisawa, and H. Yamada-Okabe.
1999.
The Candida albicans gene for mRNA 5'-cap methyltransferase: Identification of additional residues essential for catalysis.
Microbiology
145:3023-3033 |
| 46. | Yu, L., A. Martins, L. Deng, and S. Shuman. 1997. Structure-function analysis of the triphosphatase component of vaccinia virus mRNA capping enzyme. J. Virol. 71:9837-9843[Abstract]. |
| 47. |
Yue, Z.,
E. Maldonado,
R. Pillutla,
H. Cho,
D. Reinberg, and A. J. Shatkin.
1997.
Mammalian capping enzyme complements mutant Saccharomyces cerevisiae lacking mRNA guanylyltransferase and selectively binds to the elongation form of RNA polymerase II.
Proc. Natl. Acad. Sci. USA
94:12898-12903 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»